UroGen Cost Of Revenue vs Revenue Per Share Analysis

URGN Stock

USD 12.48 0.57 4.79%

UroGen Pharma financial indicator trend analysis is much more than just breaking down UroGen Pharma prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether UroGen Pharma is a good investment. Please check the relationship between UroGen Pharma Cost Of Revenue and its Revenue Per Share accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in UroGen Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

To learn how to invest in UroGen Stock, please use our How to Invest in UroGen Pharma guide.

Cost Of Revenue vs Revenue Per Share

Cost Of Revenue vs Revenue Per Share Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of UroGen Pharma Cost Of Revenue account and Revenue Per Share. At this time, the significance of the direction appears to have strong relationship.

The correlation between UroGen Pharma's Cost Of Revenue and Revenue Per Share is 0.78. Overlapping area represents the amount of variation of Cost Of Revenue that can explain the historical movement of Revenue Per Share in the same time period over historical financial statements of UroGen Pharma, assuming nothing else is changed. The correlation between historical values of UroGen Pharma's Cost Of Revenue and Revenue Per Share is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cost Of Revenue of UroGen Pharma are associated (or correlated) with its Revenue Per Share. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Revenue Per Share has no effect on the direction of Cost Of Revenue i.e., UroGen Pharma's Cost Of Revenue and Revenue Per Share go up and down completely randomly.

Correlation Coefficient

0.78

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Cost Of Revenue

Cost of Revenue is found on UroGen Pharma income statement and represents the costs associated with goods and services UroGen Pharma provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Revenue Per Share

The amount of revenue generated by a company per share of stock, calculated by dividing total revenue by the average number of shares outstanding.

Most indicators from UroGen Pharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into UroGen Pharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in UroGen Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

To learn how to invest in UroGen Stock, please use our How to Invest in UroGen Pharma guide.At this time, UroGen Pharma's Selling General Administrative is very stable compared to the past year. As of the 26th of November 2024, Tax Provision is likely to grow to about 1.2 M, while Issuance Of Capital Stock is likely to drop about 41.2 M.

UroGen Pharma fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Common Stock Shares Outstanding	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Property Plant Equipment	Long Term Debt	Common Stock Total Equity	Short Term Investments	Long Term Debt Total	Non Current Liabilities Total	Capital Surpluse	Property Plant And Equipment Gross
Total Assets		0.83	0.87	0.22	0.13	0.89	-0.26	-0.76	0.82	0.79	0.69	0.99	0.91	0.62	0.87	0.58	0.99	0.88	0.8	0.91	0.95	0.85	0.83	0.53	0.92	0.76
Other Current Liab	0.83		0.99	-0.2	-0.3	0.8	-0.01	-0.97	0.64	0.71	0.41	0.8	0.86	0.89	0.99	0.86	0.85	0.96	0.65	0.71	0.88	0.57	0.64	0.82	0.91	0.91
Total Current Liabilities	0.87	0.99		-0.17	-0.26	0.79	-0.07	-0.96	0.76	0.77	0.41	0.86	0.9	0.89	1.0	0.85	0.9	0.99	0.64	0.79	0.92	0.66	0.72	0.81	0.92	0.88
Total Stockholder Equity	0.22	-0.2	-0.17		0.99	0.24	-0.78	0.4	0.11	0.18	0.55	0.26	0.0	-0.57	-0.16	-0.63	0.13	-0.11	0.55	0.24	0.05	0.49	0.2	-0.68	-0.05	-0.02
Net Tangible Assets	0.13	-0.3	-0.26	0.99		0.19	-0.75	0.48	0.04	0.1	0.48	0.17	-0.08	-0.63	-0.26	-0.71	0.04	-0.21	0.48	0.18	-0.02	0.42	0.14	-0.75	-0.12	-0.15
Property Plant And Equipment Net	0.89	0.8	0.79	0.24	0.19		-0.25	-0.71	0.59	0.66	0.68	0.86	0.84	0.59	0.82	0.49	0.86	0.77	0.91	0.79	0.87	0.71	0.72	0.43	0.9	0.67
Net Debt	-0.26	-0.01	-0.07	-0.78	-0.75	-0.25		-0.14	-0.37	-0.54	-0.15	-0.35	-0.22	0.29	-0.06	0.41	-0.26	-0.12	-0.5	-0.41	-0.25	-0.55	-0.38	0.47	-0.14	-0.1
Retained Earnings	-0.76	-0.97	-0.96	0.4	0.48	-0.71	-0.14		-0.65	-0.66	-0.26	-0.73	-0.84	-0.97	-0.97	-0.94	-0.81	-0.93	-0.48	-0.67	-0.85	-0.47	-0.61	-0.91	-0.9	-0.8
Accounts Payable	0.82	0.64	0.76	0.11	0.04	0.59	-0.37	-0.65		0.84	0.3	0.87	0.82	0.56	0.72	0.54	0.87	0.79	0.46	0.89	0.85	0.86	0.84	0.49	0.74	0.5
Cash	0.79	0.71	0.77	0.18	0.1	0.66	-0.54	-0.66	0.84		0.25	0.86	0.83	0.52	0.75	0.46	0.85	0.79	0.63	0.84	0.84	0.78	0.8	0.41	0.78	0.65
Non Current Assets Total	0.69	0.41	0.41	0.55	0.48	0.68	-0.15	-0.26	0.3	0.25		0.63	0.43	0.09	0.43	0.12	0.56	0.41	0.77	0.43	0.46	0.64	0.38	0.07	0.47	0.53
Cash And Short Term Investments	0.99	0.8	0.86	0.26	0.17	0.86	-0.35	-0.73	0.87	0.86	0.63		0.91	0.59	0.85	0.55	0.99	0.88	0.79	0.94	0.96	0.89	0.86	0.49	0.9	0.75
Common Stock Shares Outstanding	0.91	0.86	0.9	0.0	-0.08	0.84	-0.22	-0.84	0.82	0.83	0.43	0.91		0.75	0.89	0.68	0.94	0.88	0.69	0.84	0.93	0.69	0.85	0.63	0.93	0.73
Other Current Assets	0.62	0.89	0.89	-0.57	-0.63	0.59	0.29	-0.97	0.56	0.52	0.09	0.59	0.75		0.89	0.97	0.69	0.85	0.3	0.57	0.75	0.31	0.51	0.96	0.8	0.67
Other Stockholder Equity	0.87	0.99	1.0	-0.16	-0.26	0.82	-0.06	-0.97	0.72	0.75	0.43	0.85	0.89	0.89		0.85	0.89	0.98	0.66	0.78	0.92	0.64	0.7	0.8	0.93	0.88
Total Liab	0.58	0.86	0.85	-0.63	-0.71	0.49	0.41	-0.94	0.54	0.46	0.12	0.55	0.68	0.97	0.85		0.64	0.82	0.2	0.48	0.68	0.29	0.45	1.0	0.72	0.7
Total Current Assets	0.99	0.85	0.9	0.13	0.04	0.86	-0.26	-0.81	0.87	0.85	0.56	0.99	0.94	0.69	0.89	0.64		0.91	0.74	0.94	0.98	0.83	0.86	0.59	0.94	0.75
Common Stock	0.88	0.96	0.99	-0.11	-0.21	0.77	-0.12	-0.93	0.79	0.79	0.41	0.88	0.88	0.85	0.98	0.82	0.91		0.64	0.83	0.93	0.7	0.75	0.78	0.9	0.87
Property Plant Equipment	0.8	0.65	0.64	0.55	0.48	0.91	-0.5	-0.48	0.46	0.63	0.77	0.79	0.69	0.3	0.66	0.2	0.74	0.64		0.69	0.72	0.72	0.64	0.14	0.72	0.68
Long Term Debt	0.91	0.71	0.79	0.24	0.18	0.79	-0.41	-0.67	0.89	0.84	0.43	0.94	0.84	0.57	0.78	0.48	0.94	0.83	0.69		0.95	0.86	0.88	0.43	0.85	0.57
Common Stock Total Equity	0.95	0.88	0.92	0.05	-0.02	0.87	-0.25	-0.85	0.85	0.84	0.46	0.96	0.93	0.75	0.92	0.68	0.98	0.93	0.72	0.95		0.79	0.84	0.62	0.97	0.73
Short Term Investments	0.85	0.57	0.66	0.49	0.42	0.71	-0.55	-0.47	0.86	0.78	0.64	0.89	0.69	0.31	0.64	0.29	0.83	0.7	0.72	0.86	0.79		0.73	0.23	0.68	0.54
Long Term Debt Total	0.83	0.64	0.72	0.2	0.14	0.72	-0.38	-0.61	0.84	0.8	0.38	0.86	0.85	0.51	0.7	0.45	0.86	0.75	0.64	0.88	0.84	0.73		0.4	0.76	0.55
Non Current Liabilities Total	0.53	0.82	0.81	-0.68	-0.75	0.43	0.47	-0.91	0.49	0.41	0.07	0.49	0.63	0.96	0.8	1.0	0.59	0.78	0.14	0.43	0.62	0.23	0.4		0.67	0.65
Capital Surpluse	0.92	0.91	0.92	-0.05	-0.12	0.9	-0.14	-0.9	0.74	0.78	0.47	0.9	0.93	0.8	0.93	0.72	0.94	0.9	0.72	0.85	0.97	0.68	0.76	0.67		0.74
Property Plant And Equipment Gross	0.76	0.91	0.88	-0.02	-0.15	0.67	-0.1	-0.8	0.5	0.65	0.53	0.75	0.73	0.67	0.88	0.7	0.75	0.87	0.68	0.57	0.73	0.54	0.55	0.65	0.74

Click cells to compare fundamentals

UroGen Pharma Account Relationship Matchups

UroGen Pharma fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	202.4M	122.0M	119.7M	136.2M	178.3M	98.8M
Other Current Liab	14.8M	18.2M	16.6M	17.4M	24.7M	25.9M
Total Current Liabilities	19.5M	21.4M	22.4M	23.9M	31.2M	32.8M
Total Stockholder Equity	180.3M	96.4M	8.4M	(88.7M)	(65.2M)	(62.0M)
Net Tangible Assets	180.3M	96.4M	8.4M	(89.4M)	(102.8M)	(97.6M)
Property Plant And Equipment Net	4.7M	4.2M	3.1M	3.7M	2.4M	2.1M
Net Debt	(47.1M)	(102.4M)	(44.0M)	43.7M	4.4M	4.6M
Retained Earnings	(228.0M)	(356.5M)	(467.3M)	(577.1M)	(679.3M)	(645.4M)
Accounts Payable	4.7M	3.3M	5.8M	5.5M	6.5M	4.3M
Cash	49.7M	103.9M	44.4M	55.4M	95.0M	53.3M
Non Current Assets Total	53.8M	6.4M	5.4M	6.7M	9.1M	8.5M
Cash And Short Term Investments	147.1M	103.9M	89.8M	100.0M	137.0M	79.8M
Common Stock Shares Outstanding	20.5M	21.8M	22.3M	22.8M	28.8M	17.0M
Liabilities And Stockholders Equity	202.4M	122.0M	119.7M	136.2M	178.3M	98.8M
Other Current Assets	1.0M	4.6M	8.7M	11.9M	11.1M	11.7M
Other Stockholder Equity	408.0M	452.5M	475.7M	487.8M	614.0M	644.7M
Total Liab	22.1M	25.7M	111.3M	225.0M	243.5M	255.7M
Total Current Assets	148.6M	115.6M	114.4M	128.9M	169.2M	90.2M
Accumulated Other Comprehensive Income	276K	271K	(25K)	(107K)	12K	12.6K
Common Stock	57K	60K	61K	63K	89K	93.5K
Property Plant Equipment	4.7M	4.2M	2.0M	1.3M	1.5M	1.7M
Common Stock Total Equity	57K	60K	61K	63K	72.5K	45.9K
Non Current Liabilities Total	2.6M	4.2M	89.0M	201.1M	212.3M	222.9M
Capital Surpluse	408.0M	452.5M	475.7M	487.8M	561.0M	307.7M
Property Plant And Equipment Gross	4.7M	4.2M	2.0M	1.3M	6.3M	6.6M
Non Currrent Assets Other	487K	289K	1.5M	2.7M	2.3M	2.4M
Other Assets	487K	289K	29.9K	620K	713K	367.9K
Net Invested Capital	180.3M	96.4M	8.4M	8.2M	33.3M	55.5M
Net Working Capital	129.2M	94.2M	92.0M	105.0M	138.0M	112.3M
Retained Earnings Total Equity	(228.0M)	(356.5M)	(467.3M)	(577.1M)	(519.4M)	(545.4M)
Capital Stock	57K	60K	61K	63K	89K	68.6K

Pair Trading with UroGen Pharma

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if UroGen Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in UroGen Pharma will appreciate offsetting losses from the drop in the long position's value.

Moving together with UroGen Stock

0.68	ME	23Andme Holding	Pair Corr
0.86	VALN	Valneva SE ADR	Pair Corr
0.7	JNJ	Johnson Johnson Sell-off Trend	Pair Corr

Moving against UroGen Stock

0.62	KZR	Kezar Life Sciences	Pair Corr
0.37	MLYS	Mineralys Therapeutics,	Pair Corr
0.34	MDGL	Madrigal Pharmaceuticals	Pair Corr

The ability to find closely correlated positions to UroGen Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace UroGen Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back UroGen Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling UroGen Pharma to buy it.

The correlation of UroGen Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as UroGen Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if UroGen Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for UroGen Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether UroGen Pharma offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of UroGen Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Urogen Pharma Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Urogen Pharma Stock:

How To Invest In UroGen

Details

Is UroGen Stock a good investment?

Details

What is UroGen Pharma's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in UroGen Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

To learn how to invest in UroGen Stock, please use our How to Invest in UroGen Pharma guide.

You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of UroGen Pharma. If investors know UroGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about UroGen Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(3.02)

Revenue Per Share

2.389

Quarterly Revenue Growth

0.209

Return On Assets

(0.21)

Return On Equity

(14.81)

The market value of UroGen Pharma is measured differently than its book value, which is the value of UroGen that is recorded on the company's balance sheet. Investors also form their own opinion of UroGen Pharma's value that differs from its market value or its book value, called intrinsic value, which is UroGen Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because UroGen Pharma's market value can be influenced by many factors that don't directly affect UroGen Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between UroGen Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if UroGen Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, UroGen Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

UroGen Cost Of Revenue vs Revenue Per Share Analysis

Cost Of Revenue vs Revenue Per Share

Cost Of Revenue vs Revenue Per Share Correlation Analysis

Correlation Coefficient

Cost Of Revenue

Revenue Per Share

UroGen Pharma fundamental ratios Correlations

UroGen Pharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

UroGen Pharma fundamental ratios Accounts

Pair Trading with UroGen Pharma

Moving together with UroGen Stock

Moving against UroGen Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Other Stockholder Equity	+ 1.0	Total Current Liabilities
Non Current Liabilities Total	+ 1.0	Total Liab
Cash And Short Term Investments	+ 0.99	Total Assets
Total Current Assets	+ 0.99	Total Assets
Total Current Liabilities	+ 0.99	Other Current Liab
Other Stockholder Equity	+ 0.99	Other Current Liab

Other Stockholder Equity	- 0.97	Retained Earnings
Other Current Assets	- 0.97	Retained Earnings
Retained Earnings	- 0.97	Other Current Liab
Retained Earnings	- 0.96	Total Current Liabilities
Total Liab	- 0.94	Retained Earnings
Common Stock	- 0.93	Retained Earnings